Pzena Investment Management LLC Cuts Stake in Johnson & Johnson $JNJ

Pzena Investment Management LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 245,951 shares of the company’s stock after selling 2,300 shares during the period. Pzena Investment Management LLC’s holdings in Johnson & Johnson were worth $50,900,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. AustralianSuper Pty Ltd raised its holdings in shares of Johnson & Johnson by 632.0% in the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after purchasing an additional 77,000 shares in the last quarter. J.W. Cole Advisors Inc. raised its holdings in shares of Johnson & Johnson by 2.2% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after purchasing an additional 2,769 shares in the last quarter. Guinness Asset Management LTD raised its holdings in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after purchasing an additional 5,994 shares in the last quarter. Greenberg Financial Group acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $954,000. Finally, National Pension Service raised its holdings in shares of Johnson & Johnson by 3.2% in the 3rd quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after purchasing an additional 151,707 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported that nipocalimab was approved in China, adding another growth opportunity for its immunology portfolio and reinforcing the company’s global pipeline momentum. Reuters article on nipocalimab approval in China
• Positive Sentiment: The company unveiled the Shockwave C2 Aero Coronary IVL Catheter, a next-generation device for treating calcified coronary artery disease, highlighting continued innovation in its MedTech segment. Yahoo Finance article on next-gen catheter
• Positive Sentiment: Johnson & Johnson also announced a collaboration to build a global intelligent operating room network with Abu Dhabi’s Department of Health, which could strengthen its surgical technology and AI strategy over time. Yahoo Finance article on global intelligent OR network
• Neutral Sentiment: Recent commentary from analysts and market outlets continues to frame J&J as a relatively stable large-cap healthcare name with defensive characteristics, which may be helping investors rotate into the stock during market uncertainty. Yahoo Finance article on top stock reports

Johnson & Johnson Stock Up 1.0%

JNJ stock opened at $231.69 on Friday. Johnson & Johnson has a one year low of $149.04 and a one year high of $251.71. The stock has a market capitalization of $557.73 billion, a PE ratio of 26.79, a price-to-earnings-growth ratio of 2.25 and a beta of 0.27. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a fifty day moving average of $234.19 and a 200-day moving average of $223.20.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business’s revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts expect that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s payout ratio is 60.12%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on JNJ shares. Morgan Stanley set a $283.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 15th. Guggenheim increased their target price on shares of Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Leerink Partners raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price on the stock in a research report on Wednesday, May 13th. Scotiabank reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $265.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.